Mitophagy in neurodegeneration: an opportunity for therapy?

R. X. Santos, S. C. Correia, C. Carvalho, S. Cardoso, M. S. Santos, P. I. Moreira*

*Corresponding author for this work

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Neurodegenerative disorders such as Alzheimers and Parkinsons diseases are characterized by distinct clinical manifestations and neuropathological hallmarks, but they also share common features like mitochondrial dysfunction. As strategic organelles in several cellular pathways, including life/death decision, it is crucial to maintain a healthy mitochondrial pool to ensure cellular homeostasis. Macroautophagy is a pathway of lysosomal-dependent degradation of cytosolic portions, such as misfolded proteins or damaged organelles. In the last decade this process has gained new frontiers and is currently seen as a specific, rather than a random process. In this regard the term mitophagy came to describe the selective degradation of mitochondria by autophagy. This review is intended to discuss mitochondrial dysfunction in Alzheimers and Parkinsons diseases. The recent developments on the molecular basis of mitophagy will be also argued. Finally, we will discuss mitophagy as a potential therapeutic target for neurodegenerative diseases.
Original languageEnglish
Pages (from-to)790-799
Number of pages10
JournalCurrent Drug Targets
Volume12
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Mitochondrial Degradation
Autophagy
Neurodegenerative diseases
Degradation
Neurodegenerative Diseases
Organelles
Mitochondria
Parkinson Disease
Alzheimer Disease
Random processes
Homeostasis
Therapeutics
Proteins

Keywords

  • Mitochondrial dysfunction
  • Alzheimer's disease
  • Parkinson's disease
  • mitophagy
  • potential therapy
  • neurodegeneration
  • oxidative injury
  • ROS
  • autophagy
  • pathophysiology

Cite this

Santos, R. X., Correia, S. C., Carvalho, C., Cardoso, S., Santos, M. S., & Moreira, P. I. (2011). Mitophagy in neurodegeneration: an opportunity for therapy? Current Drug Targets, 12(6), 790-799. https://doi.org/10.2174/138945011795528813

Mitophagy in neurodegeneration: an opportunity for therapy? / Santos, R. X.; Correia, S. C.; Carvalho, C.; Cardoso, S.; Santos, M. S.; Moreira, P. I.

In: Current Drug Targets, Vol. 12, No. 6, 06.2011, p. 790-799.

Research output: Contribution to journalArticle

Santos, RX, Correia, SC, Carvalho, C, Cardoso, S, Santos, MS & Moreira, PI 2011, 'Mitophagy in neurodegeneration: an opportunity for therapy?', Current Drug Targets, vol. 12, no. 6, pp. 790-799. https://doi.org/10.2174/138945011795528813
Santos RX, Correia SC, Carvalho C, Cardoso S, Santos MS, Moreira PI. Mitophagy in neurodegeneration: an opportunity for therapy? Current Drug Targets. 2011 Jun;12(6):790-799. https://doi.org/10.2174/138945011795528813
Santos, R. X. ; Correia, S. C. ; Carvalho, C. ; Cardoso, S. ; Santos, M. S. ; Moreira, P. I. / Mitophagy in neurodegeneration: an opportunity for therapy?. In: Current Drug Targets. 2011 ; Vol. 12, No. 6. pp. 790-799.
@article{8cd97c222cf54557b7b306d06116de79,
title = "Mitophagy in neurodegeneration: an opportunity for therapy?",
abstract = "Neurodegenerative disorders such as Alzheimers and Parkinsons diseases are characterized by distinct clinical manifestations and neuropathological hallmarks, but they also share common features like mitochondrial dysfunction. As strategic organelles in several cellular pathways, including life/death decision, it is crucial to maintain a healthy mitochondrial pool to ensure cellular homeostasis. Macroautophagy is a pathway of lysosomal-dependent degradation of cytosolic portions, such as misfolded proteins or damaged organelles. In the last decade this process has gained new frontiers and is currently seen as a specific, rather than a random process. In this regard the term mitophagy came to describe the selective degradation of mitochondria by autophagy. This review is intended to discuss mitochondrial dysfunction in Alzheimers and Parkinsons diseases. The recent developments on the molecular basis of mitophagy will be also argued. Finally, we will discuss mitophagy as a potential therapeutic target for neurodegenerative diseases.",
keywords = "Mitochondrial dysfunction, Alzheimer's disease, Parkinson's disease, mitophagy, potential therapy, neurodegeneration, oxidative injury, ROS, autophagy, pathophysiology",
author = "Santos, {R. X.} and Correia, {S. C.} and C. Carvalho and S. Cardoso and Santos, {M. S.} and Moreira, {P. I.}",
year = "2011",
month = "6",
doi = "10.2174/138945011795528813",
language = "English",
volume = "12",
pages = "790--799",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Mitophagy in neurodegeneration: an opportunity for therapy?

AU - Santos, R. X.

AU - Correia, S. C.

AU - Carvalho, C.

AU - Cardoso, S.

AU - Santos, M. S.

AU - Moreira, P. I.

PY - 2011/6

Y1 - 2011/6

N2 - Neurodegenerative disorders such as Alzheimers and Parkinsons diseases are characterized by distinct clinical manifestations and neuropathological hallmarks, but they also share common features like mitochondrial dysfunction. As strategic organelles in several cellular pathways, including life/death decision, it is crucial to maintain a healthy mitochondrial pool to ensure cellular homeostasis. Macroautophagy is a pathway of lysosomal-dependent degradation of cytosolic portions, such as misfolded proteins or damaged organelles. In the last decade this process has gained new frontiers and is currently seen as a specific, rather than a random process. In this regard the term mitophagy came to describe the selective degradation of mitochondria by autophagy. This review is intended to discuss mitochondrial dysfunction in Alzheimers and Parkinsons diseases. The recent developments on the molecular basis of mitophagy will be also argued. Finally, we will discuss mitophagy as a potential therapeutic target for neurodegenerative diseases.

AB - Neurodegenerative disorders such as Alzheimers and Parkinsons diseases are characterized by distinct clinical manifestations and neuropathological hallmarks, but they also share common features like mitochondrial dysfunction. As strategic organelles in several cellular pathways, including life/death decision, it is crucial to maintain a healthy mitochondrial pool to ensure cellular homeostasis. Macroautophagy is a pathway of lysosomal-dependent degradation of cytosolic portions, such as misfolded proteins or damaged organelles. In the last decade this process has gained new frontiers and is currently seen as a specific, rather than a random process. In this regard the term mitophagy came to describe the selective degradation of mitochondria by autophagy. This review is intended to discuss mitochondrial dysfunction in Alzheimers and Parkinsons diseases. The recent developments on the molecular basis of mitophagy will be also argued. Finally, we will discuss mitophagy as a potential therapeutic target for neurodegenerative diseases.

KW - Mitochondrial dysfunction

KW - Alzheimer's disease

KW - Parkinson's disease

KW - mitophagy

KW - potential therapy

KW - neurodegeneration

KW - oxidative injury

KW - ROS

KW - autophagy

KW - pathophysiology

UR - http://europepmc.org/abstract/med/21269269

U2 - 10.2174/138945011795528813

DO - 10.2174/138945011795528813

M3 - Article

C2 - 21269269

VL - 12

SP - 790

EP - 799

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 6

ER -